Short answer
VERACYTE, INC. (VCYT) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $132M (up 13.8% year over year) with net income of $19M.
Q3 2025 key financials · XBRL
- Revenue
- $132M
- +13.8% YoY · +1.3% QoQ
- Net income
- $19M
- +26.3% YoY · +2052.8% QoQ
- Operating margin
- 17.4%
- Gross margin
- 69.2%
- EPS (diluted)
- $0.24
- +20.0% YoY · +2500.0% QoQ
Source: XBRL data from the VERACYTE, INC. (VCYT) Q3 2025 10-Q on SEC EDGAR. USD.
VERACYTE, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Impact of 2025 US federal government shutdown on operations and macroeconomic volatility, including currency fluctuations and regional conflicts (Russia-Ukraine, Israel)
- Updated risk: Restructuring and deconsolidation of Veracyte SAS in August 2025 causing $20.5M impairment and decline in biopharmaceutical revenue by 74% YoY Q3
- Regulatory risk: Payer coverage pressure and cost containment tactics, including prior authorizations and Medicare reimbursement under PAMA potentially reducing testing revenue and margins
- Operational risk: Supply chain issues and single-source reagent quality affecting test turnaround times and reported test volumes, critical to near-term revenue growth
- Financial risk: Currency fluctuations and exposure impacting global operations amid macroeconomic instability and ongoing monitoring of liquidity in volatile capital markets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other VERACYTE, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.